Work

Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz253.022

Authors: E. Borazanci, A. Schram, I. Brana, M Vieito Villar, E. Garralda, A. Spreafico, M. Oliva, N. Lakhani, R. Wasserman, K. Hoffman, R. Hallett, J. Anido, P. Giblin, N. Pandya, A. Kelly, J. Seoane, D.D. Von Hoff, L.L. Siu, D.M. Hyman, J. Tabernero

Institutions: HonorHealth, Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, Princess Margaret Cancer Centre

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2978453607

FWCI: 0.091

Cites:

Cited by: 2

Related to: 10